Cisco Systems' Quarterly Earnings Preview: What You Need to Know

Barchart14:44 ET

Wall Street's Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields

Benzinga08:08 ET

Surgere Hires First Chief Revenue Officer to Drive Growth, Innovation, and Go-to-Market Strategy

Businesswire08:00 ET

Shenzhen Consys Science&Technology Co.,Ltd. (688788.SH): Cumulative repurchase of 0.9456% of its shares.

On July 31st, Gelonhui reported that Shenzhen Consys Science&Technology Co., Ltd. (688788.SH) accumulated a repurchase of 1,000,000 shares of the company through the Shanghai Stock Exchange trading system by centralized bidding trading until July 31, 2024, accounting for 0.9456% of the total share capital of 105,747,925 shares. The highest repurchase price was 39.66 yuan/share, the lowest was 23.29 yuan/share, and the total amount of funds used was RMB 37,399,873.92 (excluding transaction fees such as stamp duty and transaction commissions).

Gelonghui Finance05:47 ET

Haisco Pharmaceutical Group (002653.SZ): Sitaglipin tablets will not participate in the national 10th batch of centralized drug procurement bidding, but will participate in the 2024 medical insurance negotiation.

On July 31st, Haisco Pharmaceutical Group (002653.SZ) stated on the investor interaction platform that its Carvedilol tablets (Beichangping) will not participate in the national centralized drug procurement bidding for the tenth batch of the state, as the product belongs to innovative drugs and will participate in the 2024 medical insurance negotiation. We are actively preparing materials to participate in this round of medical insurance negotiations.

Gelonghui Finance05:17 ET

Haisco Pharmaceutical Group (002653.SZ): After 40 days on the market, the pregabalin hydrochloride capsules have been introduced to more than 10 hospitals.

Haisco Pharmaceutical Group (002653.SZ) stated on the investor interaction platform on July 31 that the innovative drug, Cligaba Sulphate Capsules (Simeoning), is expected to be approved by the end of May 2024, with commercial operation in more than 40 cities in 21 provinces within 48 hours of its release. Currently, the product is still in the market development stage and is mainly sold in outpatient pharmacies during the self-funded period. Within 40 days of its listing, it has been introduced to more than 10 hospitals.

Gelonghui Finance03:34 ET